Search research articles
Contact Us
Filters
Showing results (471-480 of 703) with videos related to
Page
of 71
Sort By:
Cancer Medicine
|
October 5, 2020
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
Grant M Fischer, Fernando C L Carapeto, Aron Y Joon, et al.
Journal for Immunotherapy of Cancer
|
April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
Cancer Research
|
October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma
Y N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.
Cancer Research
|
June 28, 2017
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
Julia Reinhardt, Jennifer Landsberg, Jonathan L Schmid-Burgk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
Page
of 71
Search research articles
Search
Showing results (471-480 of 703) with videos related to
Sort By:
Page
of 71
Cancer Medicine
|
October 5, 2020
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
Grant M Fischer, Fernando C L Carapeto, Aron Y Joon, et al.
Journal for Immunotherapy of Cancer
|
April 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
Cancer Research
|
October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma
Y N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Evan J Lipson, Sonia Dolfi, Hao Tang, et al.
Journal for Immunotherapy of Cancer
|
March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.
Cancer Research
|
June 28, 2017
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy
Julia Reinhardt, Jennifer Landsberg, Jonathan L Schmid-Burgk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, et al.
Page
of 71